drugset
drugset / Trial / NCT02439970

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

NCT02439970 ↗

Phase 3 Terminated 5 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupTriple-blindPrevention

Summary

To compare the efficacy of oral brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are CMV seronegative pretransplant and received a kidney from a CMV seropositive donor

Timeline

Start
2015-09
Primary completion
2016-01-30
Completion
2016-01-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brincidofovir Other / unclassified 100 mg Oral
Comparator Valganciclovir Small molecule 900 mg Oral

Indications

cytomegalovirus infection